Prognostic and Diagnostic Impact of TFE3 Rearrangement in Renal Cell Carcinoma

Overview

This study evaluated the clinicopathological significance of TFE3 gene rearrangement in renal cell carcinoma (RCC). TFE3-rearranged RCC, confirmed by FISH, was associated with younger patient age, higher recurrence rates, and shorter progression-free survival compared to clear cell RCC (ccRCC).

Background

Renal cell carcinoma classification has evolved to include molecular subtypes such as TFE3-rearranged RCC, part of the MiT family translocation RCCs. TFE3 gene fusions lead to protein overexpression and distinct morphological features, but diagnosis is challenging due to heterogeneous histology and limitations of immunohistochemistry (IHC). Fluorescence in situ hybridization (FISH) remains the diagnostic gold standard despite cost constraints. The incidence of TFE3-rearranged RCC is low in adults but higher in pediatric populations, with prognosis varying from indolent to aggressive disease.

Data Highlights

Multivariate Cox regression identified TFE3 rearrangement (HR=4.6; 95% CI 1.1–21.2; p=0.05), tumor size (HR=2.53; p=0.006), and metastasis presence (HR=4.36; p<0.001) as independent predictors of recurrence.

Key Findings

• TFE3-rearranged RCC patients were significantly younger than those with ccRCC (median age 49 years; p=0.02).
• The recurrence rate in TFE3-rearranged RCC was significantly higher (50%) compared to ccRCC (18%; p=0.04).
• TFE3 rearrangement was an independent prognostic factor for recurrence with a hazard ratio of 4.6 (p=0.05).
• Tumor size and presence of metastasis were also independent predictors of recurrence.
• Progression-free survival was significantly shorter in TFE3-rearranged RCC compared to ccRCC (p=0.001), while overall survival did not differ significantly.

Clinical Implications

Clinicians should consider TFE3 rearrangement status when assessing RCC prognosis, as it identifies a subset with higher recurrence risk and shorter progression-free survival. While IHC can screen for TFE3 protein expression, confirmatory FISH testing remains essential for accurate diagnosis. Awareness of this molecular subtype may guide closer surveillance and tailored management strategies.

Conclusion

TFE3-rearranged RCC represents a distinct molecular subtype with younger patient age and worse progression-free survival compared to ccRCC. Its identification via FISH is crucial for prognostication and may influence clinical management.

References

1. WHO Classification of Tumors Editorial Board 2022 -- WHO Classification of Tumors: Urinary and Male Genital Tumors
2. Argani et al. 2004 -- Xp11 Translocation Renal Cell Carcinoma
3. Kauffman et al. 2014 -- Molecular Characterization of MiT Family Translocation RCC